Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Boehringer Ingelheim
German pharmaceutical company
Nothing else this week.
- FDA
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.
- FDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- GlobeNewswireCue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights Received FDA feedback on Pre-IND Briefing Document reinforcing Company’s intention to advance investigationa